226 related articles for article (PubMed ID: 30381260)
1. Development of an aggregate-selective, human-derived α-synuclein antibody BIIB054 that ameliorates disease phenotypes in Parkinson's disease models.
Weihofen A; Liu Y; Arndt JW; Huy C; Quan C; Smith BA; Baeriswyl JL; Cavegn N; Senn L; Su L; Marsh G; Auluck PK; Montrasio F; Nitsch RM; Hirst WD; Cedarbaum JM; Pepinsky RB; Grimm J; Weinreb PH
Neurobiol Dis; 2019 Apr; 124():276-288. PubMed ID: 30381260
[TBL] [Abstract][Full Text] [Related]
2. Reducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.
Games D; Valera E; Spencer B; Rockenstein E; Mante M; Adame A; Patrick C; Ubhi K; Nuber S; Sacayon P; Zago W; Seubert P; Barbour R; Schenk D; Masliah E
J Neurosci; 2014 Jul; 34(28):9441-54. PubMed ID: 25009275
[TBL] [Abstract][Full Text] [Related]
3. Randomized phase I clinical trial of anti-α-synuclein antibody BIIB054.
Brys M; Fanning L; Hung S; Ellenbogen A; Penner N; Yang M; Welch M; Koenig E; David E; Fox T; Makh S; Aldred J; Goodman I; Pepinsky B; Liu Y; Graham D; Weihofen A; Cedarbaum JM
Mov Disord; 2019 Aug; 34(8):1154-1163. PubMed ID: 31211448
[TBL] [Abstract][Full Text] [Related]
4.
Liu Y; Yang M; Fraser K; Graham D; Weinreb PH; Weihofen A; Hirst WD; Cedarbaum JM; Pepinsky B
J Pharmacol Exp Ther; 2024 Jun; ():. PubMed ID: 38936981
[TBL] [Abstract][Full Text] [Related]
5. Differential effects of immunotherapy with antibodies targeting α-synuclein oligomers and fibrils in a transgenic model of synucleinopathy.
El-Agnaf O; Overk C; Rockenstein E; Mante M; Florio J; Adame A; Vaikath N; Majbour N; Lee SJ; Kim C; Masliah E; Rissman RA
Neurobiol Dis; 2017 Aug; 104():85-96. PubMed ID: 28476636
[TBL] [Abstract][Full Text] [Related]
6. Limited spread of pathology within the brainstem of α-synuclein BAC transgenic mice inoculated with preformed fibrils into the gastrointestinal tract.
Uemura N; Yagi H; Uemura MT; Yamakado H; Takahashi R
Neurosci Lett; 2020 Jan; 716():134651. PubMed ID: 31783082
[TBL] [Abstract][Full Text] [Related]
7. Preclinical development of a vaccine against oligomeric alpha-synuclein based on virus-like particles.
Doucet M; El-Turabi A; Zabel F; Hunn BHM; Bengoa-Vergniory N; Cioroch M; Ramm M; Smith AM; Gomes AC; Cabral de Miranda G; Wade-Martins R; Bachmann MF
PLoS One; 2017; 12(8):e0181844. PubMed ID: 28797124
[TBL] [Abstract][Full Text] [Related]
8. Alpha-Synuclein transgenic mice, h-α-SynL62, display α-Syn aggregation and a dopaminergic phenotype reminiscent of Parkinson's disease.
Frahm S; Melis V; Horsley D; Rickard JE; Riedel G; Fadda P; Scherma M; Harrington CR; Wischik CM; Theuring F; Schwab K
Behav Brain Res; 2018 Feb; 339():153-168. PubMed ID: 29180135
[TBL] [Abstract][Full Text] [Related]
9. Preclinical development of a high affinity α-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular α-synuclein and attenuate α-synuclein spreading in vivo.
Schofield DJ; Irving L; Calo L; Bogstedt A; Rees G; Nuccitelli A; Narwal R; Petrone M; Roberts J; Brown L; Cusdin F; Dosanjh B; Lloyd C; Dobson C; Gurrell I; Fraser G; McFarlane M; Rockenstein E; Spencer B; Masliah E; Spillantini MG; Tan K; Billinton A; Vaughan T; Chessell I; Perkinton MS
Neurobiol Dis; 2019 Dec; 132():104582. PubMed ID: 31445162
[TBL] [Abstract][Full Text] [Related]
10. Inoculation of α-synuclein preformed fibrils into the mouse gastrointestinal tract induces Lewy body-like aggregates in the brainstem via the vagus nerve.
Uemura N; Yagi H; Uemura MT; Hatanaka Y; Yamakado H; Takahashi R
Mol Neurodegener; 2018 May; 13(1):21. PubMed ID: 29751824
[TBL] [Abstract][Full Text] [Related]
11. The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease.
Benskey MJ; Perez RG; Manfredsson FP
J Neurochem; 2016 May; 137(3):331-59. PubMed ID: 26852372
[TBL] [Abstract][Full Text] [Related]
12. Alpha-synuclein oligomer-selective antibodies reduce intracellular accumulation and mitochondrial impairment in alpha-synuclein exposed astrocytes.
Gustafsson G; Lindström V; Rostami J; Nordström E; Lannfelt L; Bergström J; Ingelsson M; Erlandsson A
J Neuroinflammation; 2017 Dec; 14(1):241. PubMed ID: 29228971
[TBL] [Abstract][Full Text] [Related]
13. Co-aggregation of pro-inflammatory S100A9 with α-synuclein in Parkinson's disease: ex vivo and in vitro studies.
Horvath I; Iashchishyn IA; Moskalenko RA; Wang C; Wärmländer SKTS; Wallin C; Gräslund A; Kovacs GG; Morozova-Roche LA
J Neuroinflammation; 2018 Jun; 15(1):172. PubMed ID: 29866153
[TBL] [Abstract][Full Text] [Related]
14. C-terminal truncation exacerbates the aggregation and cytotoxicity of α-Synuclein: A vicious cycle in Parkinson's disease.
Ma L; Yang C; Zhang X; Li Y; Wang S; Zheng L; Huang K
Biochim Biophys Acta Mol Basis Dis; 2018 Dec; 1864(12):3714-3725. PubMed ID: 30290273
[TBL] [Abstract][Full Text] [Related]
15. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
16. Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson's Disease.
Kim S; Kwon SH; Kam TI; Panicker N; Karuppagounder SS; Lee S; Lee JH; Kim WR; Kook M; Foss CA; Shen C; Lee H; Kulkarni S; Pasricha PJ; Lee G; Pomper MG; Dawson VL; Dawson TM; Ko HS
Neuron; 2019 Aug; 103(4):627-641.e7. PubMed ID: 31255487
[TBL] [Abstract][Full Text] [Related]
17. Comparison of α-Synuclein Fibril Inhibition by Four Different Amyloid Inhibitors.
Jha NN; Kumar R; Panigrahi R; Navalkar A; Ghosh D; Sahay S; Mondal M; Kumar A; Maji SK
ACS Chem Neurosci; 2017 Dec; 8(12):2722-2733. PubMed ID: 28872299
[TBL] [Abstract][Full Text] [Related]
18. Novel conformation-selective alpha-synuclein antibodies raised against different in vitro fibril forms show distinct patterns of Lewy pathology in Parkinson's disease.
Covell DJ; Robinson JL; Akhtar RS; Grossman M; Weintraub D; Bucklin HM; Pitkin RM; Riddle D; Yousef A; Trojanowski JQ; Lee VM
Neuropathol Appl Neurobiol; 2017 Dec; 43(7):604-620. PubMed ID: 28386933
[TBL] [Abstract][Full Text] [Related]
19. Fasudil attenuates aggregation of α-synuclein in models of Parkinson's disease.
Tatenhorst L; Eckermann K; Dambeck V; Fonseca-Ornelas L; Walle H; Lopes da Fonseca T; Koch JC; Becker S; Tönges L; Bähr M; Outeiro TF; Zweckstetter M; Lingor P
Acta Neuropathol Commun; 2016 Apr; 4():39. PubMed ID: 27101974
[TBL] [Abstract][Full Text] [Related]
20. Antibodies and α-synuclein: What to target against Parkinson's Disease?
Otzen DE
Biochim Biophys Acta Proteins Proteom; 2024 Feb; 1872(2):140943. PubMed ID: 37783321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]